Sartorius from Göttingen: turnover and profit increase significantly in the 1st half of the year!

Sartorius from Göttingen: turnover and profit increase significantly in the 1st half of the year!

Göttingen, Deutschland - A little ray of hope in difficult times: Sartorius, the renowned laboratory and pharmaceutical supplier from Göttingen, is impressive in the first half of 2025. In the midst of challenging global framework conditions, the company managed to record both sales and profit growth. The current figures speak for themselves: Compared to the previous year, sales climbed by about six percent to an impressive EUR 1.77 billion (adjusted for exchange) and the adjusted profit before interest, taxes and depreciation (EBITDA) doubled almost 527 million euros. The net profit according to parts of third parties also increased and reached 81 million euros, which corresponds to an increase of one third compared to the previous year.

The new CEO Michael Grosse is optimistic and sees Sartorius on the right track of reaching the annual goals. Despite falling demand in the past two years, the company has tightened its internal structure through a savings program worth over 100 million euros, which was completed at the end of 2024. Nevertheless, the environment remains challenging: Customers hold back to new investments, as they are still reducing high stocks that they have created during the Corona pandemic.

stability and revival

The Situation stabilized according to the internal reports from Sartorius in 2024. This stability comes in a difficult environment of the life science industry, in which the demand for products and services is not always easy to predict. The significant revitalization, which could be observed in the second half of the year, especially in the final quarter.

A positive trend reversal is particularly evident in the business with consumables, where customers gradually reached their down -to -the -go destination storage stocks. Step by step, companies return to an order level that reflects the actual production activities. In the area of new therapies there are even above -average developments, which further revives the order situation.

growth of the workforce

A good news also comes from the personnel area: Sartorius increased his workforce to 13,685 employees, which is a slight increase in 157 employees compared to the end of 2024. It is particularly noteworthy that these growth in the area of production is recorded, which is a good indication of the continuing growth of the company and shows that Sartorius has a good hand to master the challenges of the industry.

All in all, Sartorius is well there despite the many hurdles. With a solid foundation and a positive view of the next few months, the company will be under discussion and on the radar of investors and industry experts.